Guideline Central Blog

• Rezlidhia (Rigel Pharmaceuticals)
  • To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.

• Brexafemme (Scynexis)
  • Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).

• Krazati (Mirati Therapeutics)
  • Targeted treatment for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

• Iyuzeh (Thea Pharma)
  • For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

• Idacio (Fresenius Kabi)
  • Multiple as biosimilar to Humira.

• Adstiladrin (Ferring Pharmaceuticals)
  • For adults with high-risk non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy.

• Vraylar (AbbVie)
  • Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults.

• Cytalux (On Target Laboratories)
  • Optical imaging agent indicated as an adjunct for intraoperative identification of malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung.

• Pemfexy (Eagle Pharmaceuticals)
  • In combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer (“NSCLC”) with no EGFR or ALK genomic tumor aberrationss

• Tymlos (Radius Health)
  • Treatment to increase bone density in men with osteoporosis at high risk of fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or in patients who have failed or are intolerant to other available osteoporosis therapy.

• Actemra (Genentech)
  • Treatment of COVID-19 in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

• Sunlenca (Gilead)
  • Treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection.

• Lunsumio (Genentech)
  • Treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.

• Wegovy (Novo Nordisk)
  • Pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity).

• Olpruva (Acer Therapeutics / Relief Therapeutics)
  • Treatment of certain patients living with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).

• Xenoview (Polarean Imaging)
  • For use with magnetic resonance imaging for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.

• Briumvi (TG Therapeutics)
  • Treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

• NexoBrid (MediWound)
  • For the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns

---

Copyright © 2023 Guideline Central, All rights reserved.